RxDoctor Payments Data

Prithipal Sethi, MD

Urology · Sacramento, CANPI 1174710578

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (38.0%), speaking fees and other — rather than concentrated in one kind of arrangement. 50 manufacturers reported payments, led by Neotract Inc. at 39.3% of the total. Reporting peaked in 2023 at $27,885 and has fallen 90.7% since, to $2,584 in 2025. Among urology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$108,994in general payments, 2019–2025

Across 460 payments — averaging $236.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$43K
  • Olympus America Inc.$20K
  • Accord Healthcare, Inc.$19K
  • Sumitomo Pharma America, Inc.$9K
  • Teleflex LLC$9K
  • Myovant Sciences Inc.$2K
  • plus $8K from 44 others
$203,558in research payments, 2019–2025

Across 27 payments — averaging $7539.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Olympus Corporation Of The Americas$128K
  • Gyrus ACMI, Inc.$36K
  • Sumitomo Pharma America, Inc.$18K
  • Teleflex LLC$12K
  • Laborie Medical Technologies Corp.$10K

What the payments were for

  • Consulting fees$41,42438%
  • Speaking & faculty fees$29,94127%
  • Travel & lodging$3,2793%
  • Food & beverage$15,12714%
  • Education$2580%
  • Other$18,96617%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$108,994 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$1,801,266
Medicare patients
923
Services billed
148,750

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide21$270,772
OrgovyxRelugolix56$141,711
GemtesaVibegron51$33,018
Methenamine Hippurate57$2,493
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst79$2,055
Tamsulosin Hcl143$1,559
Tolterodine Tartrate ErTolterodine Tartrate15$1,135
Cephalexin259$800
Bethanechol Chloride12$786
Potassium Citrate ErPotassium Citrate11$756
Finasteride42$466
Ciprofloxacin Hcl118$419
Bicalutamide23$379
Solifenacin Succinate14$322
Estradiol11$264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$639$270,77221 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$8,563$174,730107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,324 urology providers in California.

Other urology in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →